Trial record 3 of 14 for:    prochymal

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

This study is currently recruiting participants.
Verified January 2014 by Osiris Therapeutics
Information provided by (Responsible Party):
Osiris Therapeutics Identifier:
First received: November 2, 2010
Last updated: January 15, 2014
Last verified: January 2014

To provide open-label re-treatment with PROCHYMAL to subjects enrolled in companion Protocol 603 to evaluate the safety in subjects with active Crohn's disease who are resistant to standard Crohn's disease therapies.

Condition Intervention Phase
Crohn's Disease
Drug: adult human mesenchymal stem cells
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Osiris Therapeutics:

Primary Outcome Measures:
  • Disease remission [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    CDAI at or below 150 and increase in IBDQ

Secondary Outcome Measures:
  • Disease Improvement [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    CDAI response to treatments is defined as a CDAI of 150 or below, or a reduction in CDAI of at least 100 points.

  • Improvement in Quality of Life (IBDQ) [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: No ]
    IBDQ response to treatment is defined as IBDQ of 170 or above, or an increase in IBDQ of at least 16 points.

  • Number of Adverse events as a measure of safety [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: Yes ]
  • Infusional toxicity as a measure of safety and tolerability [ Time Frame: 180 Days after first infusion in Protocol 603 ] [ Designated as safety issue: Yes ]
    Infusional toxicity will be evaluated by continuously monitoring the subject's vital signs and O2 saturation by pulse oximetry from the time of PROCHYMAL administration until two hours after infusion is complete.

Estimated Enrollment: 120
Study Start Date: September 2010
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prochymal
Infusions of Prochyaml on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
Drug: adult human mesenchymal stem cells
PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
Other Names:
  • Prochymal
  • adult human mesenchymal stem cells
  • remestemcel-L

Detailed Description:

Subjects will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As subjects will be required to be in Protocol 603 during the entire duration of their participation in Protocol 611, all concomitant medication and safety information will be monitored by Protocol 603 and the combination of data from the two protocols


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have qualified for, enrolled in, and provided written ICF and authorization for use and disclosure of PHI for Protocol 603 after the August 3, 2010.
  • Subject successfully completed all screening assessments in Protocol 603 as required by Protocol 603.
  • Subject successfully completed the full course of each of the four infusions of investigational agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.
  • Subject must enroll in Protocol 611 on or before the 45th day after first infusion in Protocol 603.
  • Subject must provide written ICF and authorization for use and disclosure of PHI for Protocol 611.

Exclusion Criteria:

  • Subject is unwilling or unable to adhere to requirements of Protocol 611.
  • Subject had confirmed respiratory distress during a PROCHYMAL infusion in any prior PROCHYMAL study.
  • Subject had a serious adverse event in any previous PROCHYMAL study that was deemed by the principal investigator of that study to be possibly or probably related to PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.
  Contacts and Locations
Please refer to this study by its identifier: NCT01233960

Contact: Farrell Milstein

United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94115
United States, Florida
Clinical Research of West Florida Recruiting
Clearwater, Florida, United States, 33765
Shafran Gastroenterology Center Recruiting
Winter Park, Florida, United States, 32789
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60611
United States, Kansas
Cotton-O'Neil Clinical Research Center Recruiting
Topeka, Kansas, United States, 66606
United States, Maryland
University of Maryland, Baltimore Recruiting
Baltimore, Maryland, United States, 21201
Chevy Chase Clinical Research Recruiting
Chevy Chase, Maryland, United States, 20815
United States, Missouri
Saint Louis Center for Clinical Research Recruiting
St. Louis, Missouri, United States, 63128
St. Louis Center for Clinical Studies Recruiting
St. Louis, Missouri, United States, 63128
United States, New Hampshire
Dartmouth HItchcock Medical Center Completed
Lebanon, New Hampshire, United States, 03756
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Weill Cornell Medical College Recruiting
New York, New York, United States, 10028
United States, Tennessee
Gastroenterology Center of the Midsouth, PC Completed
Germantown, Tennessee, United States, 38138
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor University Medical Center Completed
Dallas, Texas, United States, 75246
United States, Virginia
McGuire Research Institute Recruiting
Richmond, Virginia, United States, 23249
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia
Australia, Victoria
Royal Melbourne Hospital Recruiting
Melbourne, Victoria, Australia
New Zealand
University of Otago Recruiting
Christchurch, New Zealand
Waikato Hospital Recruiting
Hamilton, New Zealand
Sponsors and Collaborators
Osiris Therapeutics
Study Director: Linda Custer, PhD Osiris Therapeutics
  More Information

No publications provided

Responsible Party: Osiris Therapeutics Identifier: NCT01233960     History of Changes
Other Study ID Numbers: 611
Study First Received: November 2, 2010
Last Updated: January 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Osiris Therapeutics:
Crohn's Disease
Adult Stem Cell Therapy
inflammation of the gastrointestinal tract

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on April 22, 2014